Ocular implant with therapeutic agents and methods thereof
View Patent ↗Implants and methods for treating ocular disorders are provided. One method involves introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber. The implant is implanted into eye tissue adjacent the anterior chamber. A therapeutic agent is eluted from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye. The therapeutic agent can be an antiproliferative agent, an anti-inflammatory drug, or a compound for treating glaucoma or ocular hypertension. The therapeutic agent can be contained within the implant or coated on the implant.
1. A method of treating an ocular disorder, comprising:
introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;
implanting the implant into eye tissue adjacent the anterior chamber such that a proximal end of the implant resides in the anterior chamber following implantation; and
eluting a therapeutic agent from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye.
2. The method of claim 1 , wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.
3. The method of claim 1 , wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.
4. The method of claim 1 , wherein the therapeutic agent is contained within the implant.
5. The method of claim 1 , wherein the therapeutic agent is coated on the implant.
6. A method of treating an ocular disorder, comprising:
forming an incision in an eye;
inserting an implant through the incision into an anterior chamber of the eye such that at least a distal end of the implant is temporarily in the anterior chamber;
implanting the implant into eye tissue such that a proximal end of the implant resides in the anterior chamber following implantation; and
eluting a therapeutic agent from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye.
7. The method of claim 6 , wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.
8. The method of claim 6 , wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.
9. The method of claim 6 , wherein the therapeutic agent is contained within the implant.
10. The method of claim 6 , wherein the therapeutic agent is coated on the implant.
11. A method of treating an ocular disorder, comprising:
introducing an implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;
placing the implant in contact with a choroid of the eye by advancing the distal end of the implant into eye tissue such that a proximal end of the implant resides in the anterior chamber following implantation; and
eluting a therapeutic agent from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent the choroid.
12. The method of claim 11 , wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.
13. The method of claim 11 , wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.
14. The method of claim 11 , wherein the therapeutic agent is contained within the implant.
15. The method of claim 11 , wherein the therapeutic agent is coated on the implant.
16. A method of treating an ocular disorder, comprising:
providing an implant having at least one anchor;
introducing the implant into an anterior chamber of an eye such that at least a distal end of the implant is temporarily in the anterior chamber;
inserting at least a portion of the implant into eye tissue at an implantation site;
using the anchor to retain the implant at the implantation site such that a proximal end of the implant resides in the anterior chamber following implantation; and
eluting a therapeutic agent from the implant into at least one of the anterior chamber, a physiologic outflow pathway of the eye, and a space adjacent a choroid of the eye.
17. The method of claim 16 , wherein the therapeutic agent comprises an antiproliferative agent or an anti-inflammatory drug.
18. The method of claim 16 , wherein the therapeutic agent comprises a compound for treating glaucoma or ocular hypertension.
19. The method of claim 16 , wherein the therapeutic agent is contained within the implant.
20. The method of claim 16 , wherein the therapeutic agent is coated on the implant.